←
Sarah Waliany, MD, MS500 posts
Sarah Waliany, MD, MS avatar✓

Sarah Waliany, MD, MS ✓

@SWaliany

Thoracic Medical Oncologist @MassGenBrigham @MGHThoracicOnc @HarvardMed | #TargetedTherapies #ADCs #EarlyDrugDevelopment #LungCancer

◷ Joined June 2019▧ 70 Photos and videos
NEJM avatar
⟳ Sarah Waliany, MD, MS retweeted
NEJM@NEJM·Oct 24

Presented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: nej.md/4iveIgW @myESMO

Post attachment
gilberto lopes avatar
⟳ Sarah Waliany, MD, MS retweeted
gilberto lopes@GlopesMd·Oct 21

Five lung cancer trials to watch at #ESMO26: DeLLphi-305 KRAScendo 1 SAFFRON OptiTROP-Lung04 OptiTROP-Lung06 Encouraging signals. Full data matter: survival, CNS activity, toxicity and quality of life. Figure separates published evidence from sponsor toplines. #LCSM

Post attachment
Stephen V Liu, MD avatar
⟳ Sarah Waliany, MD, MS retweeted
Stephen V Liu, MD@StephenVLiu·Oct 13

Pope Leo XIV has been diagnosed with lung adenocarcinoma. While we had hoped for a different diagnosis, the fact that he was able to undergo a lobectomy is encouraging. Surgery is generally pursued when lung cancer appears localized and potentially curable. Final pathology will help determine prognosis and whether additional treatment is needed. Wishing the Holy Father a smooth and speedy recovery. lombardi.georgetown.edu/lomb…

Post attachment
Stephen V Liu, MD avatar
⟳ Sarah Waliany, MD, MS retweeted
Stephen V Liu, MD@StephenVLiu·Sep 27

Update on COPERNICUS study from @BalazsHalmosMD at #WCLC26 shows impact of supportive care strategies from COCOON with 1L subcutaneous amivantamab + lazertinib for EGFR mt NSCLC. Compared to published MARIPOSA results, rate paronychia was 35% from 50%, rash 25% from 55%, VTE 3% from 23%, IRR 3% from 55%. Discontinuation of amivantamab in the first year due to AESI was < 1% (vs 9% in MARIPOSA).

Post attachmentPost attachmentPost attachmentPost attachment
Stephen V Liu, MD avatar
⟳ Sarah Waliany, MD, MS retweeted
Stephen V Liu, MD@StephenVLiu·Sep 26

Early insights into resistance to HER2 TKIs in NSCLC emerged at #WCLC26. Zongertinib & sevabertinib now both approved as 1L+ treatment for advanced NSCLC with a HER2 TKD mt. While efficacy similar, these are distinct agents and we need to learn how to leverage those differences.

Post attachmentPost attachment
Stephen V Liu, MD avatar
⟳ Sarah Waliany, MD, MS retweeted
Stephen V Liu, MD@StephenVLiu·Sep 14

Dr. @alexdrilon at #WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in pts with ROS1 NSCLC. What a waterfall plot. RR 94% with 15% CR. mPFS not reached, PFS at 6m was 96% and at 12m was 90%. Intracranial RR 100%. In 78 pts who did not have brain metastases at baseline, no CNS events occurred to date. These are fantastic outcomes.

Post attachmentPost attachmentPost attachmentPost attachment
Stephen V Liu, MD avatar
⟳ Sarah Waliany, MD, MS retweeted
Stephen V Liu, MD@StephenVLiu·Sep 12

Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm. The end of the PCI era.

Post attachment
Dr. Antonio Calles 🫁🚭 avatar
⟳ Sarah Waliany, MD, MS retweeted
Dr. Antonio Calles 🫁🚭@Tony_Calles·May 31

🌟This is history ⭐️The most awaited abstract 👏 Standing ovation at Hall B1 💊 Daraxonrasib becomes the new standard of care for patients with previously treated metastatic #pancreatic #cancer #ASCO26

Post attachment
0:07
OncLive.com avatar
⟳ Sarah Waliany, MD, MS retweeted
OncLive.com@OncLive·May 28

ALK-positive NSCLC remains one of the most rapidly evolving spaces in thoracic oncology. 🫁 Interesting data from the multicenter retrospective study led by @SWaliany evaluating continuation of next-generation ALK TKIs alongside platinum/pemetrexed chemotherapy after progression. The study suggested potential improvements in PFS/OS and reduced CNS progression, particularly in patients treated upfront with 2G/3G ALK inhibitors. Team ALKItects @PatelOncology #Fellowsforum @benlevylungdoc @Jani_Chinmay

Post attachmentPost attachmentPost attachmentPost attachment
Xiuning Le MD PhD avatar
⟳ Sarah Waliany, MD, MS retweeted
Xiuning Le MD PhD@LeXiuning·Mar 1

Please (re)watch the powerful Special Speech delivered by Dr. Ross Camidge @DRCamidge at #TTLC26 @IASLC An internationally renowned thoracic oncologist, Dr. Camidge shared something profoundly personal: his own diagnosis and treatment journey with stage IV #EGFR-mutant #NSCLC. His reflections were thoughtful and deeply human. It is a reminder that before we are physicians or patients, we are human beings: vulnerable yet resilient. Please: ❤️ Act with urgency. ❤️ Treat with respect and gentleness. ❤️ Move forward with courage and hope. @ShirishGadgeel @lungoncdoc @KarenReckampMD @TejasPatilMD

24:29
Stephen V Liu, MD avatar
⟳ Sarah Waliany, MD, MS retweeted
Stephen V Liu, MD@StephenVLiu·Feb 26

A new first line standard of care for HER2 mutant NSCLC? Zongertinib receives accelerated approval as initial therapy based on Beamion LUNG-1 trial with 1L RR 76%. Part of the new FDA voucher program, approval granted 44 days after filing! fda.gov/news-events/press-an…

Stephen V Liu, MD avatar
⟳ Sarah Waliany, MD, MS retweeted
Stephen V Liu, MD@StephenVLiu·Jan 16

Update for RET NSCLC @CCR_AACR describes acquired resistance to selective RET inhibitors. The "RETgistry" included 109 pts with post-SRI biopsies and showed 14% with secondary RET mutations. Off target included MET (18%), KRAS (7%), CDKN2A/B (5%). aacrjournals.org/clincancerr…